10 Best Long Term Healthcare Stocks to Buy

2. Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 42

5-year Revenue Growth: 121.86%

On January 28, Barclays assumed coverage of Moderna, Inc. (NASDAQ:MRNA) with an Equal Weight rating and a $25 price target as part of a broader biotechnology coverage expansion. The firm expressed a constructive view on the sector heading into 2026, citing undervaluation, expected M&A activity, and improving industry fundamentals as supportive factors.

During Moderna’s third-quarter 2025 earnings call, the company reported revenue of approximately $1.0 billion, driven primarily by sales of its approved vaccines, including Spikevax, mNEXSPIKE, and mRESVIA. Moderna, Inc. (NASDAQ:MRNA) ended the quarter with $6.6 billion in cash and investments and guided to a year-end balance of $6.5 billion to $7.0 billion. The company emphasized disciplined capital management while continuing to fund pipeline development across multiple therapeutic areas.

Moderna, Inc. (NASDAQ:MRNA) was founded in September 2010 and is headquartered in Cambridge, Massachusetts. The company focuses on developing medicines using messenger RNA technology. Moderna is second on the list of 10 best long term healthcare stocks to buy.